EMA Withdrawn: Memantine LEK (memantine hydrochloride) — Pharmathen S.A.

View source ↗

Summary

EMA has withdrawn Memantine LEK (memantine hydrochloride) from the market. The withdrawal affects treatment for Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Memantine LEK (memantine hydrochloride)

Snippet

Status: Withdrawn. Therapeutic area: Alzheimer Disease. MAH: Pharmathen S.A.. Decision date: 20/10/2020